One of the significant challenges in clinical cancer therapy is the development of tumor radioresistance, which is influenced by factors such as increased expression of gene signaling pathways, hypoxia-inducible factor 1 (HIF-1), and vascular endothelial growth factor-A (VEGF-A) [72]. This evidence concerns the gene VEGFA and cancer.